Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
NVS Novartis AG daily Stock Chart
Novartis AG
Index- P/E24.95 EPS (ttm)3.44 Insider Own- Shs Outstand2.70B Perf Week-3.08%
Market Cap232.15B Forward P/E16.11 EPS next Y5.33 Insider Trans- Shs Float2.56B Perf Month-5.72%
Income8.42B PEG3.47 EPS next Q1.26 Inst Own9.90% Short Float0.15% Perf Quarter-12.72%
Sales50.91B P/S4.56 EPS this Y16.20% Inst Trans-0.15% Short Ratio2.09 Perf Half Y-16.89%
Book/sh31.90 P/B2.69 EPS next Y4.12% ROA13.80% Target Price107.25 Perf Year-7.63%
Cash/sh2.19 P/C39.14 EPS next 5Y7.20% ROE24.10% 52W Range85.78 - 106.84 Perf YTD-4.74%
Dividend2.67 P/FCF79.23 EPS past 5Y3.20% ROI10.50% 52W High-19.66% Beta0.58
Dividend %3.11% Quick Ratio0.60 Sales past 5Y3.50% Gross Margin66.50% 52W Low0.07% ATR1.16
Employees120000 Current Ratio0.90 Sales Q/Q-6.10% Oper. Margin19.00% RSI (14)33.94 Volatility1.06% 1.02%
OptionableYes Debt/Eq0.30 EPS Q/Q-40.80% Profit Margin35.80% Rel Volume0.72 Prev Close85.95
ShortableYes LT Debt/Eq0.17 EarningsOct 27 BMO Payout36.50% Avg Volume1.83M Price85.84
Recom1.80 SMA20-2.97% SMA50-5.66% SMA200-12.87% Volume1,327,065 Change-0.13%
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Feb-29-08Downgrade HSBC Securities Neutral → Underweight
Sep-06-07Initiated UBS Buy
Jul-18-07Downgrade Credit Suisse Neutral → Underperform
Jun-01-07Reiterated Prudential Overweight $64 → $62
Nov-27-15 03:06AM  Novartiss Cosentyx: Europes First IL-17A Inhibitor for Some Uses
Nov-26-15 12:46PM  Novartis Said to Consider Selling Contact Lens Care Division at Bloomberg
10:06AM  Novartis: Market Responds to European Commissions Cosentyx Approval
Nov-25-15 05:01PM  Valeant, Glaxo, Novartis Skin Drug Prices Have Soared at Investor's Business Daily
03:57PM  Novartis: Clinical Trials Show Cosentyxs Superior Efficacy
03:56PM  Novartis Gets Expanded Cosentyx Approval from European Commission
01:10PM  Novartis Gets EU Approval for Cardiovascular Drug Entresto
Nov-24-15 08:55AM  Back To The Future The Bull Rumbles Forward at Forbes
08:23AM  Lockheed Martin Issued $7.0 Billion Worth of High-Grade Bonds
Nov-23-15 07:01PM  $160B deal to combine Pfizer and Allergan raises outcry
02:34PM  JAVELIN Series: Clinical Studies of Avelumab
02:34PM  Avelumab Receives Breakthrough Therapy Designation
01:38PM  Pharma Industry Outlook: Pricing Pressure and M&As in Focus
10:08AM  Existing Drugs for Renal Cell Carcinoma
08:46AM  3 Dividend Stocks You Don't Have to Babysit at Motley Fool
Nov-22-15 06:51PM  Report: Pfizer, Allergan close to $150 billion merger deal
Nov-20-15 06:18PM  Novartis pays $370M for drug-pushing scheme at USA TODAY
06:10PM  Novartis gets FDA approval for skin cancer drug combination Reuters
05:46PM  Novartis Admits To Valeant-like Pharmacy Scheme in $390 Million Settlement at Fortune
05:08PM  [$$] Novartis Finalizes Settlement With Justice Department at The Wall Street Journal
04:22PM  FDA approves Takeda drug for blood cancer multiple myeloma
03:30PM  CNBC update: Greek migrants detained
10:24AM  Hedge Funds Are Buying, Inc. (AMZN) at Insider Monkey
10:07AM  The Market Response to the FDAs Approval of Darzalex
06:04AM  US fines Novartis $390 mn over pharmacy kickbacks AFP
Nov-19-15 04:35PM  Novartis: FDA Accepts BLA for Biosimilar Version of Neulasta
01:15PM  Clinical Trials Demonstrated Darzalexs Efficacy Profile
01:14PM  FDA Approval of Johnson & Johnsons Darzalex for Multiple Myeloma
09:16AM  5 Things GlaxoSmithKline PLC Wants You to Know at Motley Fool
06:43AM  EU mergers and takeovers (Nov 19) Reuters
Nov-18-15 04:13PM  Novartis Announces Positive Results on Ultibro Breezhaler
12:20PM  Infinity (INFI) Completes Enrollment in Phase III DUO Study
08:13AM  Investors should look at these stocks now: Strategist
02:17AM  Novartis biosimilar takes aim at Amgen drug Neulasta Reuters
Nov-17-15 11:40AM  Why Ophthotech Corporation's Shares Soared in October at Motley Fool
09:34AM  AstraZenecas Tagrisso Approved by FDA for Lung Cancer
Nov-16-15 04:40PM  The Medicines Co. Up, Angiomax Patent Ruling Overturned
Nov-15-15 10:02AM  Billionaire Jim Simons Top High-Dividend Stock Picks at Insider Monkey
Nov-12-15 08:28AM  Novartis, Roche find "outcome-based" drug pricing an elusive dream Reuters
05:15AM  Cell And Gene Therapy: An 'Outside-In' Technology Evolution at Forbes
Nov-10-15 10:40AM  AVEO (AVEO) Swings into Earnings in Q3, Revenues Up Y/Y
Nov-09-15 05:56PM  Glaxo plans up to 20 new drug applications AAP
Nov-07-15 01:40PM  Momenta Slowed (Temporarily) at Motley Fool
Nov-06-15 12:16PM  Why XOMA Shares Are Crashing at Motley Fool
11:35AM  My proposal to lower drug prices: Expose the industry's manipulations at
08:09AM  Analyzing Pfizers Major Product Developments in 3Q15
Nov-05-15 01:00PM  New kind of "designer" immune cells clear baby's leukaemia
11:21AM  Juno, Kite, Novartis Yelp 'Oh Merde!' at Cellectis Off-the-Shelf CAR-T Data at TheStreet
10:17AM  Allergan exhibits singular approach to potential merger at Financial Times
10:11AM  Which Pfizer Products Saw Negative Growth in 3Q15?
08:30AM  Why I'm Going Long On One Of The Most Controversial Stocks On The Market
Nov-04-15 10:20AM  Is This Drug Going to Be a Big Threat to Biogen and Novartis Next Year? at Motley Fool
Nov-03-15 07:06PM  Analyzing Future Estimates for Eli Lilly and Company
06:30PM  Pick J&J, Eli Lilly, Novartis for Healthy Returns, Says Causeway Portfolio Manager at TheStreet
04:37PM  Glaxo plans up to 20 new drug applications in near term
01:08PM  Eli Lillys 3Q15 Earnings: Profitability and Financial Guidance
12:09PM  Amgens Oncology Drugs Register Solid Growth In 3Q15
08:02AM  Roche Touts New MS Drug As Legacy Players Hit Snags at Investor's Business Daily
Nov-02-15 06:06PM  Eli Lillys 3Q15 Earnings: Changes in the Animal Health Segment
05:00PM  Will AVEO (AVEO) Pull a Surprise this Earnings Season?
02:49PM  Stocks Extend Gains as Health Care Leads at TheStreet
12:28PM  Kyprolis Strengthens Amgens Position in Multiple Myeloma Segment
Oct-31-15 09:21AM  Generic Copaxone Isn't Derailing Teva Pharmaceuticals...Yet at Motley Fool
Oct-30-15 06:59PM  Bill Ackman Takes Over Valeant's Defense
03:35PM  Successful trials not all Juno needs to get cancer treatment to market at
02:25PM  Bill Ackmans Right: Big Pharma Gets Fined All the Time at Bloomberg
10:30AM  Teva's Q3 Earnings & Revenues Top Expectations, View Up
10:00AM  AbbVie Beats Q3 Views, Offers Bullish 2020 Guidance at Investor's Business Daily
04:06AM  Abraxane Expected to Strengthen Celgenes Oncology in 3Q15
Oct-29-15 04:07PM  GlaxoSmithKline's Diverging Q3 Results Imply a Long Road to Recovery at Motley Fool
10:30AM  Novartis AG Earnings Q3, 2015
09:06AM  Glaxo Up on Q3 Earnings Beat, Revenues Rise, Outlook Same
05:35AM  This drug will make your flu shot less effective at Fortune
Oct-28-15 05:10PM  Drugmaker Amgen posts big increases in 3Q profit, sales
04:45PM  Apple Upgraded, Alibaba PTs Hiked, Twitter PTs Cut at Investor's Business Daily
01:55PM  Novartis (NVS) Misses on Q3 Earnings, Maintains 2015 View
11:52AM  Eli Lillys 3Q15 Earnings: Are Revenues Growing?
11:52AM  Eli Lilly and Companys 3Q15 Earnings: An Overview
10:23AM  [$$] GlaxoSmithKline Reports Higher Sales at The Wall Street Journal
09:20AM  GlaxoSmithKline profits rise 34 percent
06:13AM  U.S. FDA warns Novartis on manufacturing violations at 2 India plants Reuters
Oct-27-15 12:59PM  European stocks end lower for 2nd straight day as oils drop weighs at MarketWatch
08:01AM  Novartis to pay $390m to settle kickback claims at Financial Times
07:41AM  Novartis (NVS) Misses Q3 Earnings & Revenue Expectations
04:17AM  European shares drop as BASF and Novartis fall
03:20AM  Novartis 3Q Profit Missed Analysts' Estimates
02:32AM  Novartis to Pay $390 Million to Settle U.S. Kickback Case at Bloomberg
02:10AM  Novartis Settles U.S. Kickback Suit as Profit Declines at Bloomberg
Oct-26-15 04:48PM  Biogen: Interferon Therapy and Tysabri Continue Modest Growth
04:48PM  Biogen Continues to Focus on Raising Tecfidera Sales in 3Q15
03:53PM  Will Headwinds Weigh on Novartis' (NVS) Earnings in Q3?
03:49PM  Novartis Afinitor, A Drug In Need Of Treatment?
10:56AM  Where traders sold Valeant
09:23AM  GlaxoSmithKline Has 4 Big Questions to Answer When It Reports Q3 Results at Motley Fool
Oct-23-15 03:23PM  Pfizers 3Q15 Revenues Expected to Fall
03:21PM  What to Expect from Pfizers 3Q15 Earnings
12:06PM  Johnson and Johnsons Major Developments in 3Q15
Oct-22-15 09:45PM  Biogen's Beat, Raise, and Yawn at Motley Fool
12:12PM  Pharma ETFs : Mergers & Deals Remain in Focus
12:06PM  Forget the plunging stock price, heres Valeants biggest problem at Fortune
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company's Alcon division provides various eye care products, including surgical, ophthalmic pharmaceuticals, and vision care products; ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers generic pharmaceuticals comprising active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as biotech manufacturing services to other companies. The company distributes its OTC products through various channels, such as pharmacies, food, drug, and mass retail outlets. Novartis AG has collaboration with Amgen Inc. in the areas of Alzheimer's disease and migraine; and an agreement with Thermo Fisher Scientific Inc. to develop a sequencing-based companion diagnostic test. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.